Health and Fitness Health and Fitness
Mon, June 14, 2010
[ 01:05 PM ] - Market Wire
DexCom To Present at the William Blair & Company 30th Annual Growth Stock Conference
[ 01:01 PM ] - Market Wire
AtriCurea?s AtriClipa" System Receives FDA 510(k) Clearance
[ 11:15 AM ] - Market Wire
AGA Medical to Present at the Wells Fargo Securities Healthcare Conference on June 23, 2010
[ 11:11 AM ] - Market Wire
Aeterna Zentaris to Present Poster on Pharmacolog .. n Oral Synthetic Growth Hormone Secretagogue/Ghre
[ 09:51 AM ] - Market Wire
Finkelstein Thompson LLP Announces Investigation of Amedisys, Inc.
[ 09:30 AM ] - Market Wire
Orthovita to Present at the Wells Fargo Securities Healthcare Conference
[ 08:54 AM ] - Market Wire
Clinical Data, Inc. Announces Closing of $32.0 Mi .. ffering Including Full Exercise of Over-Allotment
[ 08:20 AM ] - Market Wire
PPD een van de beste CROa?s van Europa in 2010
[ 08:16 AM ] - Market Wire
PPD annoverata tra le migliori organizzazioni di ricerca a contratto (CRO) da?Europa nel 2010
[ 07:52 AM ] - Market Wire
PPD ist eins der fhrenden Auftragsforschungsinstitute des Jahres 2010 in Europa
[ 07:42 AM ] - Market Wire
Curis Announces Change to Presentation Time at Th .. itya?s Mid Year Check-up on Healthcare Conference
[ 06:42 AM ] - Market Wire
NewCardio Selected to Make Presentations at 32nd .. ce of the IEEE Engineering in Medicine and Biolog
[ 06:00 AM ] - Market Wire
Bristol-Myers Squibb Signs Agreements with ICON a .. port Greater Efficiencies in Clinical Development
[ 06:00 AM ] - Market Wire
Proxy Advisory Groups Recommend Shareholders of P .. te on Tang Capital and Perceptivea?s GOLD Proxy C
[ 05:35 AM ] - Market Wire
ZIOPHARM Set to Join Russell 3000® Index
[ 05:30 AM ] - Market Wire
CytRx Set to Join the Russell 3000 Index
[ 05:00 AM ] - Market Wire
Peregrine Set to Join Russell 3000
[ 04:32 AM ] - Market Wire
Resultados actualizados del estudio Fase III dond .. inuo con REVLIMID® en pacientes recientemente di
[ 04:31 AM ] - Market Wire
Presentazione di risultati aggiornati dello Studi .. ne del trattamento continuo con REVLIMID® in paz
[ 04:31 AM ] - Market Wire
Aktualisierte Ergebnisse von Phase-III-Studie ber .. diagnostiziertem multiplem Myelom mit REVLIMID®
[ 04:30 AM ] - Market Wire
Mise jour des r©sultats de la?©tude de phaseIII .. ompu au REVLIMID® de patients r©cemment diagnos
[ 04:30 AM ] - Market Wire
Charles River to Present at Goldman Sachs and William Blair Conferences
[ 03:30 AM ] - Market Wire
Human Genome Sciences Announces Preliminary Feedb .. From FDA on ZALBINa" BLA for Chronic Hepatitis C
[ 03:00 AM ] - Market Wire
New Autism Drug Research by Cellceutix on Compoun .. nt Behavioral Changes; Chief Scientific Officer S
Sat, June 12, 2010
[ 08:10 AM ] - Market Wire
Updated Results of Phase III Study Evaluating Con .. MID® Therapy in Newly Diagnosed Multiple Myeloma
[ 07:44 AM ] - Market Wire
Dr. Reddya?s provides update on the fexofenadine- .. oephedrine 24 hour Preliminary Injunction hearing
Fri, June 11, 2010
[ 06:00 PM ] - Market Wire
Law Offices of Howard G. Smith Announces Investig .. Shareholders of IPC The Hospitalist Company, Inc.
[ 03:27 PM ] - Market Wire
Fortune River Retains First Canadian Capital Corp. for Investor Relations Services
[ 01:15 PM ] - Market Wire
Health Net Announces Appearances at Upcoming Conferences
[ 01:00 PM ] - Market Wire
Human Genome Sciences Invites Investors to Listen .. esentation at Goldman Sachs Healthcare Conference

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Goldman Sachs Healthcare Conference


Published on 2010-06-11 13:11:15 - Market Wire
  Print publication without navigation


ROCKVILLE, Md.--([ BUSINESS WIRE ])--Human Genome Sciences, Inc. (NASDAQ:HGSI) announced today that its presentation at the Goldman Sachs 31st Annual Global Healthcare Conference will be webcast and may be accessed at [ www.hgsi.com ].

A member of Human Genome Sciencesa™ senior management team will present a corporate overview on Tuesday, June 15, 2010, at 11:00 AM Eastern. Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the webcast will be available for several days after the live event.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the companya™s web site at [ www.hgsi.com ].

Contributing Sources